FDA Delays Approval of Aquestive's Anaphylm, Citing Usability Concerns in Emergency Setting
The FDA has issued a complete response letter for Aquestive's sublingual epinephrine film Anaphylm, requesting new human factors studies. The company aims to resubmit its application by Q3 2026 while advancing regulatory efforts in Europe and Canada.